JENNIFER LEIGH MCQUADE to Ipilimumab
This is a "connection" page, showing publications JENNIFER LEIGH MCQUADE has written about Ipilimumab.
Connection Strength
0.510
-
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab. JAMA Oncol. 2023 01 01; 9(1):102-111.
Score: 0.153
-
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer. 2017; 5:8.
Score: 0.102
-
Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023 10 20; 41(30):4794-4820.
Score: 0.040
-
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 04; 29(4):898-905.
Score: 0.039
-
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series. Melanoma Res. 2022 12 01; 32(6):451-459.
Score: 0.037
-
Interstitial granulomatous dermatitis and concurrent immunotherapy associated encephalitis with nivolumab and ipilimumab. Dermatol Online J. 2022 Mar 15; 28(2).
Score: 0.036
-
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. J Clin Oncol. 2022 04 01; 40(10):1068-1080.
Score: 0.036
-
Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer. 2022 03 01; 128(5):975-983.
Score: 0.035
-
Recurrent audiovestibular dysfunction and associated neurological immune-related adverse events in a melanoma patient treated with nivolumab and ipilimumab. Head Neck. 2020 11; 42(11):E35-E42.
Score: 0.032